SCHEMBL23458022

SCHEMBL23458022

Cc1cc(C)c(/C=C/C=C/c2c(C)cc(C)cc2C)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 8/20 0.39
ABCB1 P08183 1/20 0.37
HPGD P15428 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP8 P22894 1/20 0.34
MMP13 P45452 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2A6 P11509 1/20 0.32
TSHR P16473 1/20 0.32
FFAR4 Q5NUL3 2/20 0.31
F2 P00734 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23458023 1.00 RAPGEF4 (0.39) RAPGEF4ABCB1HPGDCA1CA2
SCHEMBL699401 0.88 RAPGEF4 (0.43) RAPGEF4ABCB1HPGDCA1CA2
SCHEMBL699400 0.88 RAPGEF4 (0.43) RAPGEF4ABCB1HPGDCA1CA2
Ammonia Solution, Strong SCHEMBL1984066 0.85 RAPGEF4 (0.41) RAPGEF4ABCB1HPGDCA1CA2
SCHEMBL293077 0.85 RAPGEF4 (0.33) RAPGEF4ABCB1HPGDCA1CA2
SCHEMBL28010689 0.85 RAPGEF4 (0.33) RAPGEF4ABCB1HPGDCA1CA2
SCHEMBL28401870 0.85 ABCB1 (0.37) RAPGEF4ABCB1HPGDCA1CA2
SCHEMBL293076 0.85 RAPGEF4 (0.33) RAPGEF4ABCB1HPGDCA1CA2
SCHEMBL11869222 0.78 RAPGEF4 (0.36) RAPGEF4ABCB1HPGDCA1CA2
SCHEMBL1047882 0.78 RAPGEF4 (0.36) RAPGEF4ABCB1HPGDCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12510529-B2 Method for determining authenticity and adulteration of marked petroleum hydrocarbons SICPA HOLDING SA (CH) 2025-12-30 US disclosed
EP-4069806-B1 METHOD OF MARKING A PETROLEUM HYDROCARBON SICPA HOLDING SA (CH) 2025-04-16 EP disclosed
US-20240327736-A1 METHOD OF MARKING A PETROLEUM HYDROCARBON SICPA HOLDING SA (CH) 2024-10-03 US disclosed
US-12031098-B2 Method of marking a petroleum hydrocarbon SICPA HOLDING SA (CH) 2024-07-09 US disclosed
EP-4069807-B1 METHOD FOR DETERMINING AUTHENTICITY AND ADULTERATION OF MARKED PETROLEUM HYDROCARBONS SICPA HOLDING SA (CH) 2023-10-04 EP disclosed
US-20230103579-A1 METHOD FOR DETERMINING AUTHENTICITY AND ADULTERATION OF MARKED PETROLEUM HYDROCARBONS SICPA HOLDING SA (CH) 2023-04-06 US disclosed
US-20230029106-A1 METHOD OF MARKING A PETROLEUM HYDROCARBON SICPA HOLDING SA (CH) 2023-01-26 US disclosed
EP-4069807-A1 METHOD FOR DETERMINING AUTHENTICITY AND ADULTERATION OF MARKED PETROLEUM HYDROCARBONS Sicpa Holding SA (CH) 2022-10-12 EP disclosed
EP-4069806-A1 METHOD OF MARKING A PETROLEUM HYDROCARBON Sicpa Holding SA (CH) 2022-10-12 EP disclosed
WO-2021110525-A1 METHOD FOR DETERMINING AUTHENTICITY AND ADULTERATION OF MARKED PETROLEUM HYDROCARBONS SICPA HOLDING SA (CH) 2021-06-10 WO disclosed
WO-2021110526-A1 METHOD OF MARKING A PETROLEUM HYDROCARBON SICPA HOLDING SA (CH) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12510529-B2 Method for determining authenticity and adulteration of marked petroleum hydrocarbons CYP4A11, CYP11B1, CYP11A1 RAPGEF4 3198/4885ABCB1 3241/4885HPGD 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.